Finally, in patients with stage I–III HER2+ BC treated with mastectomy and adjuvant trastuzumab ± PMRT, Lanning et al. reported a trend toward higher risk of LRR without PMRT37. The gene discussed is ERBB2; the disease is breast cancer.